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Evaluating the Bioavailability of Carbamazepine 
Using a Novel SNEDDS Formulation
Jinwon Byun, Derrick Chapman, Rebecca Kyper, Gina Mattes, and Zachary Wallace | Dr. Elisha Injeti | Cedarville University and Central State University
Background of the Problem
Carbamazepine (CBZ) is an anticonvulsant 
primarily used to treat seizures, 
glossopharyngeal neuralgia, trigeminal 
neuralgia, and acute or mixed episodes of manic 
depression. Adverse effects of its use include 
dizziness, drowsiness, nausea, headache, 
vomiting, and ataxia. CBZ is lipophilic with 
overall poor solubility and resultant 
bioavailability.
Four classes of solubility exist:
• Class I: high permeability; high solubility
• Class II: high permeability; low solubility
• Class III: low permeability; high solubility
• Class IV: low permeability; low solubility
Carbamazepine is a Class II drug. To fix this 
problem, researchers have been studying the 
use of self nano-emulsifying drug delivery 
systems (SNEDDS). Using a SNEDDS 
formulation decreases particle size to increase 
bioavailability.1 Additionally, a SNEDDS 
formulation uses oil emulsification to deliver 
these very small particles to the bloodstream 
more efficiently by increasing drug dissolution 
rate.2
Alternative Hypothesis
Objective
• Fall 2013- Submission of Research Proposal
• Spring 2014- IACUC Approval, Order Animals (~16)
• Fall 2014- Complete Experimental Methods, Collect 
Samples and Analyze Data
• Spring 2015- Data Interpretation, Repeat Experiments if 
Necessary
• Fall 2015- Submit Final Research Documentation and 
Prepare Presentation
• Spring 2016- Present in Professional Venue and for 
Research Seminar (CU)
Proposed Methods and Analysis
Limitations
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Study Design: Our study design is a randomized 
controlled crossover experiment in a rat model.
Sample: Our sample will be comprised of 10-12 
Sprague-Dawley rats divided equally into two groups.
Measurement & Data Collection: 
For the study, a tail vein method will be used to collect 
sample. The blood sample can be taken by a small 
incision on a rat’s tail. After administration, blood 
samples are collected into heparinized centrifuge tubes 
at 5, 10, 15, 20, 30, 45, 60, 90, and 120 minutes and 
stored at -20°C until ready for analysis.3 Once samples 
have been collected, our study will utilize a CEDIA kit to 
analyze blood serum carbamazepine levels.4 This 
method involves Enzyme-Linked Immunosorbent Assay 
(ELISA) analysis.
Statistical Analysis: The data we will be collecting is 
continuous data. It is being collected from two 
independent samples. Thus, an unpaired t-test will be 
used to compare the significance between the two sets 
of data. 
• Using a small sample size will lower statistical power 
of the results
• A rat model may not be generalizable to humans (can 
only make inferences)
Project Timeline
The objective of this study is to compare 
the bioavailability of a novel carbamazepine 
SNEDDS formulation to that of an existing 
FDA approved CBZ suspension.
The novel SNEDDS formulation will have a 
statistically significant increase in bioavailability 
when compared to the existing suspension.
Future Direction
Pending time and resources, research can extend beyond 
analysis of blood plasma concentrations of carbamazepine. 
Passing through the blood brain barrier is another obstacle 
present to carbamazepine. If we could also analyze the 
difference in tissue drug concentration from crossing this 
barrier, further support for use of the SNEDDS formulation 
would be uncovered. 
